Literature DB >> 6704377

Localization of a chemotactic domain in human thrombin.

R Bar-Shavit, A Kahn, M S Mudd, G D Wilner, K G Mann, J W Fenton.   

Abstract

The cyanogen bromide fragment CB67-129 of human prethrombin 1, corresponding to residues 54-116 of the thrombin B chain, is a potent chemotaxin for human peripheral blood monocytes and the murine macrophage like cell line, J774. Both of these cell types have been shown to respond chemotactically to alpha-thrombin and iPr2P-alpha-thrombin. Effective concentrations for stimulating directed cell movement with the fragment vary from 10(-11) to 10(-7) M. Moreover, CB67-129 and its parent protein compete for the same chemotactic receptor site. Fragment CB67-129, representing residues 54-116 of the human thrombin B chain sequence, contains a nine-residue insertion ("loop B") that is absent in homologous sequences derived from the closely related proteases chymotrypsin and trypsin. Unlike iPr2P-alpha-thrombin, iPr2P derivatives of these latter enzymes possess little or no chemotactic activity, suggesting a relationship between the insertion sequence and thrombin chemotactic activity. The loop B sequence is unique insofar as it contains all of the carbohydrate moieties known to reside in alpha-thrombin. However, chemotactic activity is only minimally reduced subsequent to hydrolysis by both neuraminidase and beta-galactosidase, indicating that receptor recognition and stimulated cell movement are mainly a function of structure of the cyanogen bromide derived fragment rather than of asparagine-linked carbohydrates.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6704377     DOI: 10.1021/bi00298a001

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  15 in total

Review 1.  Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more.

Authors:  R Ramachandran; M D Hollenberg
Journal:  Br J Pharmacol       Date:  2007-12-03       Impact factor: 8.739

2.  Protease-activated receptors as therapeutic targets in visceral pain.

Authors:  Nicolas Cenac
Journal:  Curr Neuropharmacol       Date:  2013-12       Impact factor: 7.363

3.  Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.

Authors:  G De Simone; A Lombardi; S Galdiero; F Nastri; R Della Morte; N Staiano; C Pedone; M Bolognesi; V Pavone
Journal:  Protein Sci       Date:  1998-02       Impact factor: 6.725

4.  Identification of a thrombin sequence with growth factor activity on macrophages.

Authors:  R Bar-Shavit; A J Kahn; K G Mann; G D Wilner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

5.  Nerve growth factor. A structural relationship between its proteolytic and leukocyte-chemotactic active sites.

Authors:  M Young; A P Gee; M D Boyle; M J Lawman; K L Munger
Journal:  Mol Cell Biochem       Date:  1985-02       Impact factor: 3.396

6.  Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1).

Authors:  N Vergnolle; M D Hollenberg; J L Wallace
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

7.  Modulation of heparin cofactor II activity by histidine-rich glycoprotein and platelet factor 4.

Authors:  D M Tollefsen; C A Pestka
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

Review 8.  Modeling thrombin generation: plasma composition based approach.

Authors:  Kathleen E Brummel-Ziedins; Stephen J Everse; Kenneth G Mann; Thomas Orfeo
Journal:  J Thromb Thrombolysis       Date:  2014-01       Impact factor: 2.300

9.  Thrombin-thrombomodulin interaction: energetics and potential role of water as an allosteric effector.

Authors:  R De Cristofaro; M Picozzi; E De Candia; B Rocca; R Landolfi
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

Review 10.  Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems.

Authors:  Kristina K Hansen; Katerina Oikonomopoulou; Yang Li; Morley D Hollenberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-10-19       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.